First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei, China.
Anhui University of Chinese Medicine, Hefei, China.
Front Endocrinol (Lausanne). 2022 Aug 9;13:945159. doi: 10.3389/fendo.2022.945159. eCollection 2022.
Osteoporosis (OP) and osteopenia are common bone disorders in old age, and lots of patients suffering from OP or osteopenia need to take antiplatelet agents to treat basic diseases. However, clinical data on the link between osteopenia or OP and antiplatelet agents are limited.
Data in this study were collected and screened from the NHANES from 2013 to 2014 and 2017 to 2018. The variables were extracted from interviews and compared between OP or osteopenia participants and normal. The relationship between OP or osteopenia and taking antiplatelet drugs was analyzed by weighted multivariate logistic regression.
After excluding individuals who were not eligible and had invalid data, we finally identified 894 participants for inclusion in the study. We found a negative association between OP or osteopenia and taking antiplatelet agents (OR = 0.53; 95% CI, 0.33-0.84; < 0.05). These results did not change on multiple imputations (OR = 0.32, 95% CI, 0.19-0.56; 0.01). In the subgroup analyses, the associations were more significant in women (OR = 0.18, 95% CI, 0.05-0.62; 0.05).
This study demonstrated that the association between OP or osteopenia and taking antiplatelet agents was significant. Therefore, it is necessary to confirm the result by extending further research.
骨质疏松症(OP)和低骨量是老年人常见的骨骼疾病,许多患有 OP 或低骨量的患者需要服用抗血小板药物来治疗基础疾病。然而,关于低骨量或 OP 与抗血小板药物之间的联系的临床数据有限。
本研究的数据来自于 2013 年至 2014 年和 2017 年至 2018 年的 NHANES 收集和筛选。从访谈中提取变量,并在 OP 或低骨量患者与正常人群之间进行比较。采用加权多变量 logistic 回归分析 OP 或低骨量与服用抗血小板药物之间的关系。
在排除不符合条件和数据无效的个体后,我们最终确定了 894 名符合条件的参与者。我们发现 OP 或低骨量与服用抗血小板药物呈负相关(OR = 0.53;95%CI,0.33-0.84; < 0.05)。多次插补后结果仍未改变(OR = 0.32,95%CI,0.19-0.56;0.01)。在亚组分析中,女性的相关性更为显著(OR = 0.18,95%CI,0.05-0.62;0.05)。
本研究表明,OP 或低骨量与服用抗血小板药物之间存在显著关联。因此,有必要通过进一步研究来证实这一结果。